at-risk was set to 0.72, and it was assumed that new dialysis modality distribution would reach by year 3. The model allowed various sensitivity analyses. RESULTS: If PD utilization increased to 25% without any reimbursement increase for PD, 5-year savings was estimated to be €13 million. If APD was reimbursed by an additional €1300 per patient, 5-year savings increased to €18 million, assuming overall PD utilization increased to 30% and APD share of PD increased from 4.5% to 30%. If APD reimbursement increased an additional €2300 per patient and APD share of PD increased to 50%, it would require 35% of all PD patients undergoing dialysis treatment to achieve €18 million savings. Finally, at this level of additional APD reimbursement, 5-year savings increase to €25 million as PD utilization increases to 40%. With €25 million in savings, an additional 1478 patient-years of treatment could be provided in Romania. CONCLUSION: With additional reimbursement for PD and the resulting increase in PD utilization, there is an opportunity for government to lower the total dialysis budget. Government can apply the savings to treat additional ESRD patients.
PUK4 IN THE UNITED KINGDOM, AN INCREASED UTILISATION OF PERITONEAL DIALYSIS THERAPY COULD LEAD TO AN INCREASE IN THE NUMBER OF PATIENTS BEING TREATED FOR RENAL REPLACEMENT THERAPY (RRT)
Sondhi S 1 , Walker DR 2 1 Baxter Healthcare, Newbury, Berks, UK, 2 Baxter Healthcare Corporation, McGaw Park, IL, USA OBJECTIVES: There is expected to be an increase in the number of patients needing dialysis in the UK over the next 5 years. Outcomes for the different modalities available, haemodialysis (HD) and peritoneal dialysis (PD), have been shown to be similar yet the majority of dialysis patients are treated with HD. Any changes in dialysis delivery that could lead to a more efficient use of resources could increase the number of RRT patients that could be treated. The objective of this evaluation is to project a five-year impact on total dialysis costs when there is a hypothesised shift in modality from HD to PD. METHODS: An Excelbased budget impact model was used to estimate the impact of a shift in modality utilisation. The model takes into account dialysis modality shares, annual average cost of treating patients per modality, annual RRT growth rate and years to reach new modality distribution. Cost data from a recent UK study were used. At baseline (June 2007) there were 23,133 RRT patients undergoing dialysis therapy, 79% using HD and 21% using PD. Annual direct cost per patient was £39,412 for HD, £20,764 for home HD (HHD), £22,350 for automated PD (APD), and £16,355 for continuous ambulatory PD (CAPD). Total costs included drug treatment and transport costs. At baseline, 2% of the HD population was on HHD and 48% of the PD population was on CAPD. RESULTS: If PD utilisation increases to 30% (of which 60% is APD) by 2011, the cumulative 5-year budget is reduced by a total of £166 million. This cumulative 5-year savings can provide an additional 5,036 patient-years of treatment. CONCLUSIONS: In the UK, an increased use of PD provides an opportunity to treat additional patients within a fixed budget, which is a potential solution to the increased demand for RRT in the coming years. 
PUK7 A COST-MINIMIZATION ANALYSIS OF OXYBUTYNIN (TRANSDERMAL DELIVERY SYSTEM) COMPARED TO TOLTERODINE (TABLETS) IN THE TREATMENT OF PATIENTS WITH URGE OR MIXED URINARY INCONTINENCE IN SWEDEN
Sverre JM, Holm LB, Kristensen FKO PharmEcon, Asker, Akershus, Norway OBJECTIVES: Standard medicinal care of patients with urge or mixed urinary incontinence is muscarinic receptor antagonists. Alternative forms of administration are available for these drugs. The objective of this analysis was to compare the cost effectiveness of the only available transdermal oxybutynin patch with oral long-acting tolterodine tablets in the treatment of patients with urge or mixed urinary incontinence in Sweden.
METHODS:
The efficacy of oxybutynin patches (3.9 mg/day), and tolterodine tablets (4 mg/day) was compared in a 12 weeks randomized clinical trial with 361 patients. The study demonstrated a comparable clinical efficacy between the treatment alternatives in number of daily incontinence episodes, average void volume and QoL. A cost minimization analysis (CMA) was performed based on this trial where direct medical costs related to drug treatments and the costs of treating the major adverse events (AE) (erythema, pruritus, rash, dry mouth, diarrhoea and constipation) were included. Resource utilization associated with the treatment of the adverse events in Swedish clinical practice was assessed by Swedish specialists in the field. RESULTS: The CMA shows that the total costs for 12 weeks tolterodine treatment is 1113.-SEK (~119.-€) per patient while the total costs for 12 weeks oxybutynin treatment is 1067.-SEK (~114.-€) . The results also demonstrate that the cost of treating AEs compose an insignificant fraction of the total treatment costs. This is due to the low frequency of AEs requiring treatment, together with the low costs for treating each AE. A number of sensitivity analyses demonstrate the robustness of the results, including various scenarios for extrapolating the findings over 52 weeks. CONCLU-SION: This CMA finds that oxybutynin patches (3.9 mg/day) is a cost-effective treatment alternative to tolterodine tablets (4 mg/ day) for treating patients with urged or mixed urinary incontinence in Sweden. (1EUR = 3.8PLN) . RESULTS: Indirect comparison of immunosuppressive therapy schemes were taken into account: TAC + AZA + GCS and MMF + CsA + GCS (CsA + AZA + GCS as common comparator). Review of RCTs for these therapies included in indirect comparison revealed no significant differences in their effectiveness and safety. TAC use was associated with significantly higher costs from public payer's perspective compared to MMF (difference: 97457PLN-135616PLN) per therapy in accordance with assumed reimbursement category for MMF (lump co-payment-50% co-payment). Sensitivity analysis confirmed that MMF's scheme was cheaper compared to TAC's scheme from public payer's perspective in Poland. CONCLU-SION: MMF's therapeutic scheme use in place of TAC's scheme lead to significant savings for public payer in kidney transplant immunosuppressive therapy in Poland.
PUK8

CMA OF MYCOPHENOLAN MOFETIL (MMF; CELLCEPT) OR TACROLIMUS (TAC; PROGRAF) IN KIDNEY TRANSPLANT IMMUNOSUPPRESSIVE THERAPY SCHEMES FROM PUBLIC PAYER'S PERSPECTIVE IN POLAND
